Active Volume Stocks: TCF Financial Corporation (NYSE:TCF), Corcept Therapeutics Incorporated (NASDAQ:CORT)

u.s stocks

TCF Financial Corporation (NYSE:TCF)

BMO Capital Maintains TCF Financial Corporation (NYSE:TCF)’s stock to Market Perform with the price target of $26. This rating was issued on 10/23/18. The stock recently closed its previous session at $20.69 by showing a percentage change of -0.48% from its previous day closing price of $20.79.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on TCF Financial Corporation (NYSE:TCF) in which Raymond James Maintains TCF Financial Corporation (NYSE:TCF) to Outperform by settling a price target of $24 on 10/23/18. Bank of America Upgrades the stock to Buy on 9/06/18 with no specific Price Target. Morgan Stanley Maintains the company’s stock to Equal-Weight on 7/31/18 by setting a price target of $27. BMO Capital Downgrades TCF Financial Corporation (NYSE:TCF) to Market Perform with a price target of $28.

TCF Financial Corporation (NYSE:TCF) currently has a consensus Price Target of $25.13. While some analysts have a High Price target for the stock of $28 and a Low Price Target of $23.

Several sell side analysts reviewed their recommendations on TCF Financial Corporation (NYSE:TCF) where 1 analyst have rated the stock as Strong Buy, 4 analysts said it’s a Buy, 11 rated the stock as Hold, 1 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 2.67. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, TCF Financial Corporation (NYSE:TCF) reported its Actual EPS of $0.51/share. The analysts offering Earnings Estimates for the company were believing that TCF Financial Corporation (NYSE:TCF) could bring EPS of $0.48/share. The difference between Actual EPS and Estimated EPS was 0.03 Percent. Thus the company showed an Earnings Surprise of 6.3 Percent.

TCF Financial Corporation (NYSE:TCF) has a market capitalization of 3.47 Billion. The stock traded with the volume of 1.2 Million shares in the last trading session. The stock touched its high share price of $27.34 on 06/11/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 11/13/17 as $17.00. The company has a 1 Year high price target of $25.13. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -10.07%. The Moving Average SMA50 is -15.4% while SMA200 is -14.63%.

TCF Financial Corporation (NYSE:TCF) is currently showing its ROA (Return on Assets) of 1.2%. The Return on Investment (ROI) is at 27.4% while it’s Return on Equity (ROE) value stands at 11.4%. The stock currently shows its YTD (Year to Date) performance of 0.93 percent while its Weekly performance value is -7.88%. The Monthly and Yearly performances are -12.96 percent and 19.66 percent respectively. The Relative Volume value measured for TCF Financial Corporation (NYSE:TCF) is 0.97. The Average Volume (3 months) is 1.23 Million.

The stock currently has its Annual Dividend of $0.6 and an annual Dividend Yield of 2.9 Percent. TCF has P/E (Price to Earnings ttm) value of 19.95, Forward P/E of 10.68, P/C (Price to cash per share) of 5.12 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 78.5 percent.

Company Profile:

TCF is a Wayzata, Minnesota-based national financial holding company. TCF has banking offices in Minnesota, Illinois, Michigan, Wisconsin, Colorado and Indiana. Other TCF affiliates provide leasing and equipment finance, mortgage banking, discount brokerage, and investments and insurance sales. They are a national financial holding company of one federally chartered bank, TCF National Bank.

Corcept Therapeutics Incorporated (NASDAQ:CORT)

Cantor Fitzgerald Initiates Coverage On Corcept Therapeutics Incorporated (NASDAQ:CORT)’s stock to Neutral with the price target of $17. This rating was issued on 8/23/18. The stock recently closed its previous session at $11.63 by showing a percentage change of -1.11% from its previous day closing price of $11.76.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on Corcept Therapeutics Incorporated (NASDAQ:CORT) in which B. Riley FBR Maintains Corcept Therapeutics Incorporated (NASDAQ:CORT) to Buy by settling a price target of $22 on 8/13/18. Stifel Nicolaus Downgrades the stock to Hold on 5/31/18 with no specific Price Target. B. Riley FBR Initiates Coverage On the company’s stock to Buy on 3/09/18 by setting a price target of $30. Stifel Nicolaus Initiates Coverage On Corcept Therapeutics Incorporated (NASDAQ:CORT) to Buy with a price target of $20.

Corcept Therapeutics Incorporated (NASDAQ:CORT) currently has a consensus Price Target of $16.7. While some analysts have a High Price target for the stock of $27.5 and a Low Price Target of $6.

Several sell side analysts reviewed their recommendations on Corcept Therapeutics Incorporated (NASDAQ:CORT) where 1 analyst have rated the stock as Strong Buy, 1 analysts said it’s a Buy, 2 rated the stock as Hold, 1 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 2.4. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Corcept Therapeutics Incorporated (NASDAQ:CORT) reported its Actual EPS of $0.14/share. The analysts offering Earnings Estimates for the company were believing that Corcept Therapeutics Incorporated (NASDAQ:CORT) could bring EPS of $0.24/share. The difference between Actual EPS and Estimated EPS was -0.1 Percent. Thus the company showed an Earnings Surprise of -41.7 Percent.

Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of 1.35 Billion. The stock traded with the volume of 1.2 Million shares in the last trading session. The stock touched its high share price of $25.96 on 01/29/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 10/26/18 as $11.27. The company has a 1 Year high price target of $16.7. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -10.4%. The Moving Average SMA50 is -14.95% while SMA200 is -28.12%.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is currently showing its ROA (Return on Assets) of 69.6%. The Return on Investment (ROI) is at 85% while it’s Return on Equity (ROE) value stands at 80.3%. The stock currently shows its YTD (Year to Date) performance of -35.6 percent while its Weekly performance value is -4.44%. The Monthly and Yearly performances are -15.29 percent and -36.27 percent respectively. The Relative Volume value measured for Corcept Therapeutics Incorporated (NASDAQ:CORT) is 0.94. The Average Volume (3 months) is 1.28 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. CORT has P/E (Price to Earnings ttm) value of 8.2, Forward P/E of 11.35, P/C (Price to cash per share) of 8.53 and Price to Free Cash Flow (P/FCF) value of 16.04. The stock is showing its Operating Margin of 35.7 percent.

Company Profile:

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol. It is developing its lead product, CORLUX for the treatment of the psychotic features of psychotic major depression. Corcept Therapeutics Incorporated is headquartered in Menlo Park, California.